3 Penny Stocks to Watch Now, 3/31/26
TipRanks (Tue, 31-Mar 10:13 AM ET)
Globe Newswire (Mon, 30-Mar 4:46 PM ET)
Artelo Biosciences Soars 230% on Obesity Push — Why Is ARTL Stock Now Crashing?
TipRanks (Mon, 30-Mar 5:39 AM ET)
Artelo Biosciences Secures $11 Million in Private Placement—Key Takeaways for Investors
Market Chameleon (Fri, 27-Mar 7:07 AM ET)
Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Globe Newswire (Fri, 27-Mar 10:40 AM ET)
Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments
Globe Newswire (Wed, 25-Mar 4:05 PM ET)
Artelo Biosciences Broadens Therapeutic Reach with Fully Funded Entry into $16.3B Glaucoma Market
Market Chameleon (Wed, 25-Mar 3:53 AM ET)
Globe Newswire (Wed, 25-Mar 7:31 AM ET)
Biotech Breakthroughs and Strategic Pivots Fuel Market Momentum
Globe Newswire (Wed, 18-Mar 10:41 AM ET)
Market Chameleon (Wed, 18-Mar 5:53 AM ET)
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
Artelo Biosciences trades on the NASDAQ stock market under the symbol ARTL.
As of March 31, 2026, ARTL stock price declined to $7.58 with 2,060,924 million shares trading.
ARTL has a beta of -0.21, meaning it tends to be less sensitive to market movements. ARTL has a correlation of 0.00 to the broad based SPY ETF.
ARTL has a market cap of $5.58 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, ARTL traded as high as $85.80 and as low as $2.96.
The top ETF exchange traded funds that ARTL belongs to (by Net Assets): VXF.
ARTL has underperformed the market in the last year with a return of -51.9%, while SPY returned +17.6%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ARTL shares. However, ARTL has outperformed the market in the last 3 month and 2 week periods, returning +107.1% and +56.3%, while SPY returned -4.4% and -2.8%, respectively. This indicates ARTL has been having a stronger performance recently.
ARTL support price is $6.80 and resistance is $10.67 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARTL shares will trade within this expected range on the day.
